BRMU8602968U - medicine "ramipril + metformin" in combination form for cardiovascular disease - Google Patents

medicine "ramipril + metformin" in combination form for cardiovascular disease

Info

Publication number
BRMU8602968U
BRMU8602968U BRMU8602968-1U BRMU8602968U BRMU8602968U BR MU8602968 U BRMU8602968 U BR MU8602968U BR MU8602968 U BRMU8602968 U BR MU8602968U BR MU8602968 U BRMU8602968 U BR MU8602968U
Authority
BR
Brazil
Prior art keywords
insulin
ramipril
cardiovascular disease
metformin
cardiovascular
Prior art date
Application number
BRMU8602968-1U
Other languages
Portuguese (pt)
Inventor
Jr Walter Santos
Original Assignee
Jr Walter Santos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jr Walter Santos filed Critical Jr Walter Santos
Priority to BRMU8602968-1U priority Critical patent/BRMU8602968U/en
Priority to PCT/BR2007/000345 priority patent/WO2008058354A2/en
Publication of BRMU8602968U publication Critical patent/BRMU8602968U/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

O MEDICAMENTO "RAMIPRIL + METFORMINA " EM FORMA COMBINADA PARA DOENçAS CARDIOVASCULARES. Resume-se a combinação de dois medicamentos utilizados contra as doenças cardiovasculares são a principal causa de morte no mundo globalizado. Há nitida correlação entre o ganho ponderal e o excesso de peso com risco de doenças cardiovasculares. O excesso de peso predispóe a estas doenças devido anormalidades no metabolismo dos lípides, glicose e pressão arterial. A resistência à insulina / hiperinsulinemia parece ser um fator de risco independente de outros fatores de risco associados, como a obesidade, hiperlipidemia e hipertensão, tanto em homens como em mulheres. A insulina e os fatores de crescimento semelhantes à insulina estimulam a atividade das células musculares lisas e estão envolvidas na aterogénese e mesmo na reestenose que se segue ao reparo coronário pela angioplastia. Outros efeitos da insulina estão relacionados aos mecanismos que contribuem para o desenvolvimento tanto da hipertensão como da dislipidemia. O MEDICAMENTO "RAMIPRIL + METFORMTNA" EM FORMA COMBINADA PARA DOENCAS CARDIO VASCULARES, diminuindo a resistência insulínica, a pressão arterial, o ganho ponderal e melhorando o perfil lipídico destes paciente, reduziriam muito a probabilidade de eventos cardiovasculares e consequentemente o óbito dessa natureza em nossa população."RAMIPRIL + METFORMIN" MEDICINAL PRODUCT COMBINED FOR CARDIOVASCULAR DISEASES. In short, the combination of two drugs used against cardiovascular disease is the leading cause of death in the globalized world. There is a clear correlation between weight gain and overweight with risk of cardiovascular disease. Overweight predisposes to these diseases due to abnormalities in lipid metabolism, glucose and blood pressure. Insulin resistance / hyperinsulinemia appears to be a risk factor independent of other associated risk factors such as obesity, hyperlipidemia and hypertension in both men and women. Insulin and insulin-like growth factors stimulate smooth muscle cell activity and are involved in atherogenesis and even restenosis following coronary repair by angioplasty. Other effects of insulin are related to the mechanisms that contribute to the development of both hypertension and dyslipidemia. "RAMIPRIL + METFORMTNA" COMBINED FOR CARDIO VASCULAR DISEASES, decreasing insulin resistance, blood pressure, weight gain and improving the lipid profile of these patients would greatly reduce the likelihood of cardiovascular events and consequently the death of this nature in our country. population.

BRMU8602968-1U 2006-11-16 2006-11-16 medicine "ramipril + metformin" in combination form for cardiovascular disease BRMU8602968U (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BRMU8602968-1U BRMU8602968U (en) 2006-11-16 2006-11-16 medicine "ramipril + metformin" in combination form for cardiovascular disease
PCT/BR2007/000345 WO2008058354A2 (en) 2006-11-16 2007-11-14 Descriptive report of the 'patent of invention of the medicament 'ramipril + metformin in combined form for cardiovascular diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRMU8602968-1U BRMU8602968U (en) 2006-11-16 2006-11-16 medicine "ramipril + metformin" in combination form for cardiovascular disease

Publications (1)

Publication Number Publication Date
BRMU8602968U true BRMU8602968U (en) 2008-09-30

Family

ID=39402022

Family Applications (1)

Application Number Title Priority Date Filing Date
BRMU8602968-1U BRMU8602968U (en) 2006-11-16 2006-11-16 medicine "ramipril + metformin" in combination form for cardiovascular disease

Country Status (2)

Country Link
BR (1) BRMU8602968U (en)
WO (1) WO2008058354A2 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265375A1 (en) * 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets

Also Published As

Publication number Publication date
WO2008058354A3 (en) 2009-04-02
WO2008058354A2 (en) 2008-05-22

Similar Documents

Publication Publication Date Title
BRMU8602999U (en) medicine "rosuvastatin + metformin" in combination form for cardiovascular disease
Belcaro et al. Efficacy and safety of Meriva®, a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients
Jouad et al. Hypoglycaemic effect of Rubus fructicosis L. and Globularia alypum L. in normal and streptozotocin-induced diabetic rats
da Luz et al. Red wine and equivalent oral pharmacological doses of resveratrol delay vascular aging but do not extend life span in rats
Arnaoutis et al. The effect of hypohydration on endothelial function in young healthy adults
Hennekens et al. Aspirin in the treatment and prevention of cardiovascular disease: past and current perspectives and future directions
Kokkinaki et al. Chemically synthesized Secoisolariciresinol diglucoside (LGM2605) improves mitochondrial function in cardiac myocytes and alleviates septic cardiomyopathy
WO2008058355A3 (en) Descriptive report of patent of invention of the medicament 'atorvastatin + metformin' in combined form for cardiovascular diseases
ECSP055914A (en) PHARMACEUTICAL COMBINATION FOR THE PREVENTION OR THERAPY OF CARDIOVASCULAR, CARDIOPULMONARY, PULMONARY OR RENAL DISEASES
Rokyta et al. Post-pyloric enteral nutrition in septic patients: effects on hepato-splanchnic hemodynamics and energy status
Li et al. TRPM8 activation improves energy expenditure in skeletal muscle and exercise endurance in mice
US20160346340A1 (en) Compositions including milk thistle and methods for the treatment of various disorders using the same
BRMU8602970U (en) medicine "telmisartam + metformin" in combination form for cardiovascular disease
BRMU8602968U (en) medicine "ramipril + metformin" in combination form for cardiovascular disease
Nettelblad et al. Psoralens used for cosmetic sun tanning: an unusual cause of extensive burn injury
BRMU8602991U (en) medicine "candesartan + metformin" in combination form for cardiovascular disease
BRMU8403463U (en) combined medicine amlodipine + metformin in combination form for cardiovascular disease
BRMU8602979U (en) medicine "atorvastatin + metformin" in combination form for cardiovascular disease
BRMU8403417U (en) simvastatin + metformin combined medicine for cardiovascular disease
Jacob Effects of yoga in type 2 diabetes mellitus with hypertension: Alteration in RBC morphology as a marker for oxidative stress
BRMU8403462U (en) valsartan + metformin in combination form for cardiovascular disease
CN106727480B (en) Fex-3 is preparing the application in anti-obesity drug
BRMU8403482U (en) "enalapril + metformin" in combination form for cardiovascular disease
Mani et al. Metformin targeting complex I: A future anticancer drug
Pascoe-González et al. Acetylsalicylic Acid Administered in Patients with Type 2 Diabetes Mellitus and Its Effect on the Antioxidant Enzyme System

Legal Events

Date Code Title Description
B03A Publication of an application: publication of a patent application or of a certificate of addition of invention
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE AS 4A E 5A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2156 DE 02/05/2012.